The Valley Desk

NCT04634825 · Interventional trial

Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Overall registry status Terminated

Phase 2

Conditions Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov